Zhongshan Innovation New Drug Development Co. Ltd. has described conjugates comprising a chelating ligand moiety, a fibroblast activation protein α (FAP) ligand and integrin αvβ3 or integrin αvβ6 ligand and a linker. They are reported to be potentially useful for the diagnosis and/or treatment of cancer.
Chinese Academy of Medical Sciences has divulged imidazopyridine derivatives reported to be useful for the treatment of Acinetobacter infections, particularly A. baumannii infections.
Chengdu Zeling Biomedical Technology Co. Ltd. has identified salts of deuterated compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Simcere Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising E3 ubiquitin-protein ligands coupled to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety via a linker reported to be useful for the treatment of cancer and inflammatory disorders.
Simcere Pharmaceutical Co. Ltd. has described stachybotrys microspore triprenyl phenols (SMTPs) acting as plasminogen activators reported to be useful for the treatment of thromboembolism.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged pentacyclic derivatives reported to be useful for the treatment of autoimmune disease.